Among these mutations, ERBB2 is a hotspot mutation in breast cancer that can induce RAS/RAF/MAPK-signaling pathway activity, and the NF1 deletion mutation is also involved in MAPK activation (Razavi et al. 2018). The gene discussed is ERBB2; the disease is breast carcinoma.